共 14 条
[1]
Combining thrombolysis with the platelet glycoprotein Ⅱ b/Ⅲa inhibitor lamifiban: results of the platelet aggregation receptor antagonist dose investigation and reperfu sion gain in myocardial infarction (PARADIGM)trial. The PARADIGM investigators. Journal of the American College of Cardiology . 1998
[2]
Design and methodology of the PURSULT trial:evaluating eptifibatide for acute ischemic coronary syndromes.Platelet glycoprotein Ⅱ b Ⅲ a in unstable angina:receptor suppression using integrilin therapy. Harrington RA. The American Journal of Cardiology . 1997
[3]
Oral glycoprotein Ⅱ b/Ⅲ a inhibition with orbofiban in patients with coronary syndromes(OPUSTIMI 16) trial. Canon CP,McCabe CH. Wilcox RG. et al. Circulation . 2000
[4]
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. The PRISM study investidators. The New England Journal of Medicine . 1998
[5]
Antiplatelet agents in cardiology: The choice of therapy. Steven R,Steinhubl MD. The Annals of Thoracic Surgery . 2000
[6]
Increased mortality with oral platelet glycoprotein Ⅱb/Ⅲ a antagonists. Chew D,Bhatt DL,Sapp SK,et al. Circulation . 2001
[7]
Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome:an OPUS-TIMI 16 substudy. Holmes MB. Sobel BE,Connon CP,et al. The American Journal of Cardiology . 2000
[8]
Tirofiban(Aggrastar~R). Cook JJ,Bednar B,Lymch JL,et al. Cardiovascular Drugs . 1999
[9]
Use of a monoclonal antibady directed against the platelet glycoprotein Ⅱ b/Ⅲ a receptor in high-risk coronary angioplasty. EPIC investigators. The New England Journal of Medicine . 1994
[10]
Platelet glycoprotein Ⅱb/Ⅲ a receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG investigators. The New England Journal of Medicine . 1997